Larimar Therapeutics, Inc. (LRMR)
| Market Cap | 455.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -165.67M |
| Shares Out | 103.88M |
| EPS (ttm) | -2.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,294,936 |
| Open | 4.450 |
| Previous Close | 4.440 |
| Day's Range | 4.325 - 4.470 |
| 52-Week Range | 1.730 - 6.420 |
| Beta | 1.02 |
| Analysts | Strong Buy |
| Price Target | 16.50 (+276.28%) |
| Earnings Date | May 6, 2026 |
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for LRMR stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 276.28% from the latest price.
News
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
* Pro forma cash, cash equivalents, and marketable securities of $244.5 million reflects $136.9 million of cash, cash equivalents and marketable securities as of December 31, 2025 combined with the $1...
Larimar Therapeutics Transcript: The Citizens Life Sciences Conference 2026
A novel protein replacement therapy for Friedreich's ataxia demonstrated robust increases in frataxin levels and clinical improvements, surpassing current standards. Regulatory engagement has been collaborative, with a BLA submission and phase III trial planned for mid-2024, supported by strong financials.
Larimar Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Breakthrough Therapy designation was achieved, with regulatory alignment on frataxin as a surrogate endpoint and a global Phase III trial set to begin U.S. enrollment in Q2. The focus is on pediatric patients, with a flexible market strategy and promising efficacy data compared to competitors.
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Laminar Therapeutics Stock Is Popping Today: What's Going On?
Larimar Therapeutics Inc (NASDAQ: LRMR) shares are jumping on Wednesday after multiple analysts reiterated their bullish outlook.
Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation
The designation covers adults and children with the rare disease and was based on data from an ongoing open-label study. Here's what investors need to know.
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA's review of available clinical data from open label study FDA written communi...
Larimar Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
A novel therapy for Friedreich's ataxia shows promise in raising frataxin levels above the critical threshold, improving clinical outcomes and potentially modifying disease progression. Accelerated approval is being pursued, with a phase III trial and regulatory updates underway.
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...
Top 3 Health Care Stocks That May Rocket Higher In December
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriers Consistent directional improve...
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR
LOS ANGELES , Oct. 16, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or "the Company") (NASDAQ: LRMR)...
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , Oct. 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Larimar Therapeutics...
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR
LOS ANGELES--(BUSINESS WIRE)--Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR.
Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study
Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg injec...
Larimar Therapeutics Transcript: Study Update
Nomlabofusp demonstrated robust increases in frataxin and consistent improvements in key clinical outcomes for Friedreich's ataxia, including mFARS, ADL, fine motor coordination, and fatigue, with a favorable safety profile aside from manageable allergic reactions. Accelerated approval is targeted for 2026.
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia
BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia
Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT
Larimar Therapeutics Reports Second Quarter 2025 Financial Results
* Pro forma cash, cash equivalents, and marketable securities of $203.6 million reflects $138.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 combined with the $65.1 ...
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Announces Proposed Underwritten Public Offering
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia
BALA CYNWYD, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...